TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease

European Journal of Pharmacology

Volumn 620, Issue 1-3, 2009, Pages 42-48

  Ikeda, Ken ^a   Yoshikawa, Satoru ^a   Kurokawa, Takahiro ^a   Yuzawa, Natsumi ^a   Nakao, Kaoru ^a   Mochizuki, Hidenori ^a  

^a TORAY INDUSTRIES INC   (Japan)

Author keywords

Dyskinesia; Kappa opioid receptor; Parkinson's disease; TRK 820

Indexed keywords

DOPAMINE; KAPPA OPIATE RECEPTOR; LEVODOPA; NALFURAFINE; NORBINALTORPHIMINE; OXIDOPAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DYSKINESIA; INHIBITION KINETICS; MALE; MICRODIALYSIS; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RAT; ROTATION; TREATMENT DURATION;

AMANTADINE; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DYSKINESIAS; EXTRACELLULAR SPACE; LEVODOPA; MALE; MICRODIALYSIS; MORPHINANS; NEOSTRIATUM; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; ROTATION; SPIRO COMPOUNDS; TIME FACTORS;

EID: 70349094450     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.08.013     Document Type: Article

References (35)

1. Bezard E., Brefel C., Tison F., Peyro-Saint-Paul H., Ladure P., Rascol O., and Gross C.E. Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey. Prog. Neuropsychopharmacol. Biol. Psychiatry 23 (1999) 1237-1246
2. Blanchet P.J., Konitsiotis S., and Chase T.N. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov. Disord. 13 (1998) 798-802
3. Cenci M.A. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci. 30 (2007) 236-243
4. Cenci M.A., Lee C.S., and Björklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. NeuroSci. 10 (1998) 2694-2706
5. Chopin P., Colpaert F.C., and Marien M. Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J. Pharmacol. Exp. Ther. 288 (1999) 798-804
6. Cox H., Togasaki D.M., Chen L., Langston J.W., Di Monte D.A., and Quik M. The selective kappa-opioid receptor agonist U50, 488 reduces L-Dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates. Exp. Neurol. 205 (2007) 101-107
7. 3 receptor agonist rotigotine antihemiparkinsonian actions. Eur. J. Pharmacol. 599 (2008) 81-85
8. Dykstra L.A., Gmerek D.E., Winger G., and Woods J.H. Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J. Pharmacol. Exp. Ther. 242 (1987) 413-420
9. Endoh T., Matsuura H., Tajima A., Izumimoto N., Tajima C., Suzuki T., Saitoh A., Suzuki T., Narita M., Tseng L., and Nagase H. Potent antinociceptive effects of TRK-820, a novel κ-opioid receptor agonist. Life Sci. 65 (1999) 1685-1694
10. Giuffra M., Mouradian M.M., Davis T.L., Ownby J., and Chase T.N. Dynorphin agonist therapy of Parkinson's disease. Clin. Neurophamacol. 16 (1993) 444-447
11. Hefti F., Melamed E., and Wurtman R.J. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res. 195 (1980) 123-137
12. Hudson J.L., van Horne C.G., Strömberg I., Brock S., Clayton J., Masserano J., Hoffer B.J., and Gerhardt G.A. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res. 626 (1993) 167-174
13. Hughes N.R., McKnight A.T., Woodruff G.N., Hill M.P., Crossman A.R., and Brotchie J.M. Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism. Mov. Disord. 13 (1998) 228-233
14. Johansson P.A., Andersson M., Andersson K.E., and Cenci M.A. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of L-DOPA-induced dyskinesia. Neurobiol. Dis. 8 (2001) 220-239
15. Kumagai H., Matsukawa S., and Utsumi J. Itch. Basic Mechanisms and Therapy (2004), Marcel Dekker, New York, NY 279-286
16. Kuzmin A., Sandin J., Terenius L., and Ögren S.O. Dose- and time-dependent bimodal effects of κ-opioid agonists on locomotor activity in mice. J. Pharmacol. Exp. Ther. 295 (2000) 1031-1042
17. Lane E.L., Cheetham S., and Jenner P. Dopamine uptake inhibitor-induced rotation in 6-hydoroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenalin receptors. J. Pharmacol. Exp. Ther. 312 (2004) 1124-1131
18. Luginger E., Wenning G.K., Bösch S., and Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesia in Parkinson's disease. Mov. Disord. 15 (2000) 873-878
19. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., and Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. NeuroSci. 15 (2002) 120-132
20. Madras B.K., Fahey M.A., Goulet M.G., Lin Z., Bendor J., Goodrich C., Meltzer P.C., Elmaleh D.R., Livni E., Bonab A.A., and Fischman A.J. Dopamine transporter (DAT) inhibitors alleviate specific parkinsonian deficits in monkeys: association with DAT occupancy in vivo. J. Pharmacol. Exp. Ther. 319 (2006) 570-585
21. Marin C., Bové J., Bonastre M., and Tolosa E. Effect of acute and chronic administration of U50, 488, a kappa opioid receptor agonist, in 6-OHDA-lesioned rats chronically treated with levodopa. Exp. Neurol. 183 (2003) 66-73
22. Mayeux R. Epidemiology of neurodegeneration. Annu. Rev. Neurosci. 26 (2003) 81-104
23. Meissner W., Ravenscroft P., Reese R., Harnack D., Morgenstern R., Kupsch A., Klitgaard H., Bioulac B., Gross C.E., Bezard E., and Boraud T. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol. Dis. 22 (2006) 586-598
24. Meshul C.K., and McGinty J.F. Kappa opioid receptor immunoreactivity in the nucleus accumbens and caudate-putamen is primarily associated with synaptic vesicles in axons. Neuroscience 96 (2000) 91-99
25. Nakao K., Ikeda K., Kurokawa T., Togashi Y., Umeuchi H., Honda T., Okano K., and Mochizuki H. Effect of TRK-820, a selective κ opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis. Nihon Shinkei Seishin Yakurigaku Zasshi 28 (2008) 75-83
26. Obeso J.A., Olanow C.W., and Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23 (2000) S2-S7 (Suppl)
27. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1997), Academic Press, San Diego, CA, USA
28. Samadi P., Bédard P.J., and Rouillard C. Opioids and motor complications in Parkinson's disease. Trends Pharmacol. Sci. 27 (2006) 512-517
29. Snow B.J., Macdonald L., Mcauley D., and Wallis W. The effect of amantadine on levodopa-induced dyskinesia in Parkinson's disease: a double blind, placebo-controlled study. Clin. Neuropharmacol. 23 (2000) 82-85
30. Togashi Y., Umeuchi H., Okano K., Ando N., Yoshizawa Y., Honda T., Kawamura K., Endoh T., Utsumi J., Kamei J., Tanaka T., and Nagase H. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur. J. Pharmacol. 435 (2002) 259-264
31. Umeuchi H., Togashi Y., Honda T., Nakao K., Okano K., Tanaka T., and Nagase H. Involvement of central μ-opioid system in the scratching behavior in mice, and the suppression of it by the activation of κ-opioid system. Eur. J. Pharmacol. 477 (2003) 29-35
32. Ungerstedt U., and Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 24 (1970) 485-493
33. Westin J.E., Vercammen L., Strome E.M., Konradi C.K., and Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 62 (2006) 800-810
34. Wikström B., Gellert R., Ladefoged S.D., Danda Y., Akai M., Ide K., Ogasawara M., Kawashima Y., Ueno K., Mori A., and Ueno Y. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blinded, placebo-controlled clinical studies. J. Am. Soc. Nephrol. 16 (2005) 3742-3747
35. Yoshikawa S., Hareyama N., Ikeda K., Kurokawa T., Nakajima M., Nakao K., Mochizuki H., and Ichinose H. Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models. Eur. J. Pharmacol. 606 (2009) 102-108